STAY CURRENT with FDA-Approved Immunotherapy Treatments

2019-2020 ACI SERIES
From September 2019 through March 2020, the upcoming ACI series includes programs in the following cities*:

- Cleveland - Sept. 5, 2019
- Chicago - Sept. 28, 2019
- Boston - Oct. 10, 2019
- Buffalo, N.Y. - Oct. 26, 2019
- Philadelphia - Nov. 12, 2019
- San Francisco - Nov. 14, 2019
- Nashville, Tenn. - Dec. 4, 2019
- San Diego - Dec. 12, 2019
- Birmingham, Ala.
- Charlotte, N.C.
- San Antonio
- Tampa, Fla.
- Tucson, Ariz.
- Washington, D.C.
- Vancouver, B.C.

*Please visit sitcancer.org/aci for more information.

ACI PROGRAM TAKEAWAYS
ACIs are presented by local authorities in tumor immunology and cancer immunotherapy and cover the following topics:

- Treating patients with FDA-approved immunotherapies
- Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identifying and managing irAEs
- Employing strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Applying foundational knowledge for clinical implementation of SITC’s Cancer Immunotherapy Guidelines
- Anticipating forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Recognizing common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

For full accreditation information and to register for these events, please visit: sitcancer.org/aci
The 2019–2020 Advances in Cancer Immunotherapy™ educational series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.

WHY ATTEND?

• Earn CME, CPE and CNE credits and MOC points
• Attend for FREE if you are a healthcare professional, student, patient or patient advocate
• Hear from and network with local experts in tumor immunology and cancer immunotherapy

ACCREDITATION INFORMATION

AMA Credit Designation
This activity has been approved for AMA PRA Category 1 Credit(s)™.

Pharmacist Credit Designation
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation
This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

Thank you to our dedicated organizers who make our ACI live programs so engaging and impactful:

CLEVELAND-SEPT. 5, 2019
Pauline Funchain, MD – Cleveland Clinic Cancer Center
Brian Rini, MD – Cleveland Clinic Cancer Center
Jung-Min Song, CNP, RN – Cleveland Clinic Cancer Center

CHICAGO-SEPT. 28, 2019
Lisa Ha, RN – Northwestern Medicine
Jeffrey A. Sosman, MD – Northwestern University
Derek A. Wainwright, PhD – Northwestern University

BOSTON-OCT. 10, 2019
Elizabeth Buchbinder, MD, PhD – Dana-Farber Cancer Institute
David F. McDermott, MD – Beth Israel Deaconess Medical Center
Virginia Seery, MSN, RN, ANP-BC – Beth Israel Deaconess Medical Center

BUFFALO, N.Y.-OCT. 26, 2019
Christos Fountzilas, MD – Roswell Park Comprehensive Cancer Center
Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center
Cheryl Raczyk, PA – Roswell Park Comprehensive Cancer Center

PHILADELPHIA-NOV. 12, 2019
Hossein Borghaei, MS, DO – Fox Chase Cancer Center
Anthony J. Olszanski, MD, RPh – Fox Chase Cancer Center

SAN FRANCISCO-NOV. 14, 2019
Terence Friedlander, MD – University of California San Francisco
Lissa Gray, NP – University of California San Francisco
Katy K. Tsai, MD – University of California San Francisco

NASHVILLE, TENN.-DEC. 4, 2019
Suzanne Jones, PharmD – Sarah Cannon
Jeffrey C. Rathmell, PhD – Vanderbilt University School of Medicine
Anil Shanker, PhD – Meharry Medical College School of Medicine

SAN DIEGO-DEC. 12, 2019
Christopher Coyne, MD, MPH – University of California San Diego
Sandip P. Patel, MD – University of California San Diego Health
Ilia M. Saunders, PharmD, BCOP – University of California San Diego

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. (as of Aug. 21, 2019).

For full accreditation information and to register for these events, please visit sitcancer.org/aci